FDA eyes 1st schizophrenia drug in decades
For the first time in decades, the FDA has approved a new type of schizophrenia drug
The FDA has approved KarXT, the first new type of drug for schizophrenia in decades. It appears to be effective, but its main advantage over current treatments is milder side effects.
FDA eyes 1st schizophrenia drug in decades: 5 things to know
The FDA is set to make a pivotal decision Sept. 26 about KarXT, a novel antipsychotic developed by Karuna Therapeutics. If approved, it would be the first drug with a unique mechanism for treating schizophrenia in decades, Medscape reported Sept. 20.
The FDA is expected to approve a new type of schizophrenia drug
The Food and Drug Administration is expected to approve KarXT, the first new type of drug for schizophrenia in decades. It appears to be effective, but its main advantage is milder side effects.
FDA eyes first schizophrenia drug shift in decades
The Food and Drug Administration is slated to decide Thursday whether to approve the first new schizophrenia drug in at least three decades. Why it matters: The complex condition is currently treated with antipsychotics that carry safety risks like metabolic disorders,
FDA To Consider Approving First New Schizophrenia Drug In Over 30 Years
During clinical trials, Bristol Myers Squibb's KarXT was said to offer better treatment with fewer side effects. Meanwhile, Pfizer's sickle cell disease treatment Oxbryta was withdrawn from all markets over concerns about the risk of a painful complication and death.
Bristol-Myers Acquired Drug KarXT Poised For FDA Approval As First New Type Of Schizophrenia Treatment In 70 Years
KarXT, a novel schizophrenia drug, is on the verge of FDA approval, promising to revolutionize treatment. However, access challenges within the US healthcare system could limit its impact on mental health care.
Hosted on MSN23h
Psilocybin vs Lexapro; FDA's KarXT Decision Nears; Obesity and Schizophrenia
In a phase II trial of moderate-to-severe major depressive disorder, 6 weeks of intensive treatment with psilocybin or ...
BioSpace3d
Schizophrenia Space Anticipates First-in-Class FDA Approval for BMS’ KarXT
With an FDA action date of Sept. 26, Bristol Myers Squibb’s KarXT could soon be the first new type of schizophrenia drug in ...
The 'game-changing' treatment for schizophrenia
US poised to approve KarXT as new antipsychotic treatment for disorder, which could offer reduced side-effects ...
Schizophrenia: the new drug set to tackle the ‘cancer of psychiatry’
But the healthcare system in the US still struggles to provide adequate care for those with serious mental illness ...
BioSpace3d
5 Schizophrenia Candidates Chasing BMS’ KarXT
As the FDA prepares to render a verdict on BMS’ closely watched schizophrenia drug, BioSpace takes a closer look at the ...
Medscape6d
Will 'Game Changer' Antipsychotic Live Up to the Hype?
The FDA is poised to issue a decision soon on KarXT, a potential first-in-class antipsychotic for schizophrenia. What should ...